New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
08:02 EDTXNCRXencor initiates Phase 1 study of XmAb7195 for asthma
Xencor announced that the first subject has been dosed in a Phase 1a clinical trial of XmAb7195, a monoclonal antibody engineered to suppress IgE via three distinct mechanisms of action as a potential treatment for asthma and other atopic disease. The Phase 1 trial will evaluate safety, pharmacokinetics and immunogenicity of a single ascending dose of XmAb7195 in a total of 64 subjects.
News For XNCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for XNCR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use